# Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Source: https://onco.cc/trials/nct04623541/  
OnCo record `nct04623541` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Epcoritamab, Prednisone, Cyclophosphamide, Doxorubicin, Rituximab and Vincristine in chronic lymphocytic leukaemia, run by Genmab, active and no longer recruiting.

## Summary

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome is a phase 1/2 interventional study registered as NCT04623541 by Genmab, with 194 participants enrolled, started 2020-11-25 and due to reach its primary completion in 2027-12. Interventions recorded: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide and Pirtobrutinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04623541
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- Sponsor: Genmab
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT04623541: https://clinicaltrials.gov/study/NCT04623541

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rituximab](https://onco.cc/drugs/rituximab/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct04623541.json